OncLive SOSS

Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

FOLFIRI Plus Encorafenib and Cetuximab Is Active in BRAF V600E–Mutant mCRC

September 15th 2024, 1:27pm

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC

September 14th 2024, 10:20pm

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC

September 14th 2024, 10:10pm

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC

September 14th 2024, 8:00pm

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

September 14th 2024, 7:50pm

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

Zipalertinib Demonstrates Safety, Disease Control in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024, 7:41pm

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLC

September 14th 2024, 7:15pm

Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.

Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer

September 14th 2024, 7:06pm

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

TILs May Prognosticate Survival Benefit With Treatment De-escalation in Early HER2+ Breast Cancer

September 14th 2024, 7:00pm

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

KEYNOTE-A18 Data Support Pembrolizumab Plus Chemoradiotherapy as New SOC in High-Risk Locally Advanced Cervical Cancer

September 14th 2024, 6:32pm

Pembrolizumab plus chemoradiotherapy improved survival in previously untreated, high-risk locally advanced cervical cancer.

Encorafenib/Binimetinib Exhibits Anti-Tumor Activity in Untreated BRAF-Mutant Advanced NSCLC

September 14th 2024, 6:14pm

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

Neoadjuvant Dato-DXd Plus Durvalumab Shows Variable pCR Rates in Stage II/III Breast Cancer

September 14th 2024, 5:47pm

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

Pembrolizumab Improves Survival for Gastric/GEJ Adenocarcinoma

September 14th 2024, 5:45pm

Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.

Low-Dose Pembrolizumab May Prove Equal Efficacy as a Standard Dose for Stage IV NSCLC

September 14th 2024, 5:19pm

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.

Frontline Zanidatamab Plus Chemo ± Bevacizumab Is Safe, Active in HER2+ mCRC

September 14th 2024, 4:59pm

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

First-Line T-DXd Combinations Show Early Antitumor Activity in HER2+ Gastric/GEJ Cancers

September 14th 2024, 4:28pm

First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

September 14th 2024, 4:25pm

Adjuvant pembrolizumab and chemotherapy with or without radiation showed mixed findings in patients with high-risk endometrial cancer.

NVL-655 Shows Strong Efficacy in Heavily Pretreated ALK+ NSCLC

September 14th 2024, 4:17pm

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14th 2024, 4:15pm

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

September 14th 2024, 3:55pm

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.